Specialty medications continue to dominate pharmacy spend, now accounting for 52% of all U.S. pharmaceutical sales, according to a recent report from the Healthcare Distribution Alliance. With costs often reaching tens — or even hundreds — of thousands of dollars per year, solutions like MedBen Rx’s biosimilar program are becoming essential.
MedBen Rx clients that have implemented our biosimilar program are realizing average savings of up to 95% compared to brand-name specialty medications, without sacrificing safety or clinical effectiveness. When a biosimilar is added to the formulary, MedBen Rx works directly with providers to ensure a seamless transition for members.
To help clients more efficiently capture these savings, MedBen Rx recently introduced an advance notice model for biosimilars. Clients receive a 60-day notice before new biosimilars are automatically added to their formulary, providing transparency while simplifying administration. And as more biosimilars enter the market, MedBen Rx will continue to make them available at the lowest possible cost.